# US 2026/0306439 A1 · Trem2 agonists for the stimulation of microglia and methods of identification

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0306439 A1
- Document ID: US20260306439A1
- Status: Published application
- Kind: A1
- Application number: 19/710,262
- Filed: 2026-06-16
- Published: 2026-10-08
- Earliest claimed: 2017-10-17
- Assignees: The Translational Genomics Research Institute
- Applicants: The Translational Genomics Research Institute
- Inventors: Isabelle Schrauwen; Matthew Huentelman; Wayne Jepsen
- Web page: https://patentgrep.com/patent/US20260306439A1

## CPC

- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/421: 1,3-Oxazoles, e.g. pemoline, trimethadione
- G01N 33/5023: {on expression patterns}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure is directed to methods of promoting phagocytosis, particularly the phagocytic activity of microglia via activation of triggering receptor expressed on myeloid cells 2 (TREM2). The present disclosure is also directed to methods of activating TREM2 in a cell, particularly a neuronal cell exhibiting an accumulation of a pathogenic protein. The present disclosure is directed to detecting an effect of a compound on the TREM2 activity as well.

## Claims

### Claim 1

A method of activating a triggering receptor expressed on myeloid cells 2 (TREM2) in a cell, comprising contacting the cell with a compound selected from the group consisting of: Tyrphostin AG 538, AC1NS458, IN1040, Butein, Okanin, AGL 2263, GB19, GB16, GB20, GB17, GB18, GB21, GB22, GB27, GB44, GB42, GB2, 4,4′-Dihydroxychalcone, 3,4-Dihydroxybenzophenone, derivatives thereof, and salts thereof, wherein the amount of the compound is sufficient to activate TREM2 in the cell.

### Claim 2 (depends on 1)

The method of any one of claim 1, wherein the cell is selected from the group consisting of: a mononuclear phagocyte, a dendritic cell, a granulocyte, a bone marrow-derived macrophage, a monocyte-derived macrophage, a tissue macrophage, a Kuppfer cell, an alveolar macrophage, an osteoclast, and a circulating monocyte.

### Claim 3 (depends on 2)

The method of claim 2, wherein the mononuclear phagocyte is selected from the group consisting of: microglia, osteoclast, and alveolar macrophage, and wherein the tissue macrophage is splenocyte.

### Claim 4 (depends on 1)

The method of claim 1, further comprising selecting the cell based on TREM2 upregulation.

### Claim 5 (depends on 4)

The method of claim 4, wherein the cell is microglia in the central nervous system (CNS).

### Claim 6

A method of detecting an effect of a compound on the triggering receptor expressed on myeloid cells 2 (TREM2) activity, comprising the steps of:
applying the compound to the host cell, wherein the host cell expresses TREM2 and TYRO protein tyrosine kinase binding protein (TYROBP) and the host cell has a synthetic sequence comprising an NFAT-response element and a nucleotide sequence encoding a reporter; and
measuring a signal emitted by the reporter in the host cell.

### Claim 7 (depends on 6)

The method of claim 6, wherein the reporter is selected from the group consisting of: firefly luciferase, chloramphenicol acetyltransferase (CAT), β-galactosidase (LacZ), a blue/UV protein, a cyan protein, a green fluorescent protein (GFP), a yellow protein, an orange protein, a red fluorescent protein (RFP), a far-red protein, a near-IR protein, a long stokes shift protein, a photoactivatible protein, a photoconvertable protein, and a photoswitchable protein.

### Claim 8 (depends on 7)

The method of claim 7, wherein the reporter comprises firefly luciferase.

### Claim 9 (depends on 8)

The method of claim 8, further comprising deriving an EC50 value of the compound in the host cell.

### Claim 10 (depends on 9)

The method of claim 9, further comprising measuring the signal emitted by the reporter in the host cell before applying the compound.

### Claim 11 (depends on 10)

The method of claim 10, further comprising:
applying the compound to a negative control cell;
measuring a signal emitted by the reporter in the negative control cell; and
selecting the compound as a TREM2 agonist if the signal produced by the compound in the host cell is at least 5 fold higher than the signal in the negative control cell.

### Claim 12 (depends on 11)

The method of claim 11, wherein the negative control cell expresses an undetectable amount of TREM2, TYROBP, or both.

### Claim 13 (depends on 12)

The method of claim 12, wherein the expression of TREM2 protein in the negative control cell is less than 5% of the expression of TREM2 protein in the host cell.

### Claim 14 (depends on 13)

The method of claim 13, wherein the expression of TYROBP protein in the negative control cell is less than 5% of the expression of TYROBP protein in the host cell.

### Claim 15 (depends on 14)

The method of claim 14, further comprising:
measuring a signal emitted by the reporter in a positive control cell, wherein the positive control cell has the synthetic sequence comprising the NFAT-response element and the nucleotide sequence encoding the reporter; and
selecting the compound as a TREM2 agonist if the signal produced by the compound in the host cell is at least 50% of the signal in the positive control cell.

### Claim 16 (depends on 15)

The method of claim 15, further comprising applying phorbol myristate acetate (PMA) and a Ca2+ ionophore to the positive control cell.

### Claim 17 (depends on 16)

The method of claim 16, wherein the Ca2+ ionophore is ionomycin.

### Claim 18 (depends on 15)

The method of claim 15, further comprising applying an agonist of the TREM2 signaling pathway to the positive control cell.

### Claim 19 (depends on 18)

The method of claim 18, wherein the positive control cell is the host cell.

### Claim 20 (depends on 19)

The method of claim 19, further comprising plating the host cell, the negative control cell, the positive control cell, or combinations thereof in a 384-well plate.
